BRIEF—Teikoku and Link agree deal to market Lidoderm in China

The US business of Japan’s Teikoku Pharma has agreed an exclusive license agreement with Link Health Group for the latter to develop market, sell, and distribute Lidoderm (lidocaine) in China.

Link will be responsible for Chinese registration and development of the product, which is sold in the USA and Europe as Versatis.

Link chief executive Yan Song said he was “very confident in its registration and development, under the current policy by CFDA.”

Under the terms of the agreement, Link Health will pay TPU near-term milestones, including an upfront cash payment, an additional milestone payment based upon the timing of CFDA approval, as well as sales milestones and double-digit royalties on net sales.